Madrigal Pharmaceuticals Financials - Benzinga

Madrigal Pharmaceuticals Inc

MDGLNASDAQ

Trade with Public

Trade with Public

$513.02

-5.81-1.12%

近くで: Sep 22, 5:00 PM EST

$513.02

-5.81-1.12%

プレマーケット: 3:00 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Madrigal Pharmaceuticals Financials

Madrigal Pharmaceuticals (MDGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per

Benzinga Newsdesk

PRO
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate

Benzinga Newsdesk

Earnings Scheduled For February 19, 2026

Benzinga Insights

Earnings Preview For Madrigal Pharmaceuticals

Benzinga Insights

© 2026 Benzinga | All Rights Reserved